Skip Navigation



Annals of Oncology Advance Access published online on May 25, 2006
Annals of Oncology, doi:10.1093/annonc/mdl097
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/8/1313    most recent
mdl097v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Greystoke, A.
Right arrow Articles by Steward, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greystoke, A.
Right arrow Articles by Steward, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received February 22, 2006
Revised March 29, 2006
Accepted March 30, 2006

original article

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

A. Greystoke 1, S. Blagden 1, A. L. Thomas 2, E. Scott 2, G. Attard 1, R. Molife 1, L. Vidal 1, S. Pacey 1, D. Sarkar 1, A. Jenner 3, J. S. De-Bono 1, and W. Steward 2 *

1 Drug Development Unit, Royal Marsden Hospital, Sutton, UK
2 Leicester Royal Infirmary, Leicester, UK
3 Daiichi Pharmaceuticals UK Ltd, London, UK

* To whom correspondence should be addressed.
W. Steward, E-mail: wps1{at}leicester.ac.uk


  Abstract

Background: TZT-1027 is a tubulin-binding drug and synthetic derivative of dolastatin-10 with cytotoxic and antivascular activity in vitro and in vivo. Studies have demonstrated anti-tumour activity in several tumour types.

Methods: Patients were treated with escalating doses of TZT-1027 and carboplatin at doses from 1.6 to 2.0 mg/m2 and AUC 4 and 5 respectively. For pharmacokinetic analysis, plasma sampling was done during the first course using a high-performance liquid chromatographic assay.

Results: 14 patients received a total of 55 cycles at three dose levels. Dose limiting toxicities (DLTs) were first observed with 1.6mg/m2 TZT-1027 and carboplatin AUC 5; 1 patient had grade 4 neutropenia and a delay in day 8 treatment occurred in two patients (gr 2 fatigue, gr 3 diarrhoea). At TZT-1027 2 mg/m2 and carboplatin AUC 5, one patient experienced grade 3 paralytic ileus. The most frequent toxicities were neutropenia, anaemia, fatigue, constipation, infection and vomiting. Peripheral neuropathy was reported in 36% of patients. One patient (pancreatic adenocarcinoma) achieved a partial response lasting 181 days. Pharmacokinetic analysis did not demonstrate any interaction between TZT-1027 and carboplatin.

Conclusions: The recommended phase II dose is TZT-1027 1.6mg/m2 and carboplatin AUC 5. No evidence of a PK interaction between these agents was observed.

Keywords: carboplatin; dolastatin 10 analogue; phase I; solid tumours; TZT-1027.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.